Dr. Kevin Petrecca, William Feindel Chair in NeuroOncology at the Montreal Neurological Institute and Hospital of McGill University and the MUHC, enrolled and treated Canada’s first patient in a new clinical trial for patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection. “Brain tumors are extremely challenging to treat, and with 27 Canadians diagnosed each day there is an urgent need for new therapies,” said Dr. Petrecca. “This trial using cancer-selective gene therapy is the kind of cutting-edge investigational treatment that we want to offer patients at our site – the largest specialized neuroscience research and clinical center in Canada. Our team is thrilled to be the first site to open the Toca 5 study in Canada.”
Dr. Gelareh Zadeh, Wilkins Family Chair in Brain Tumor Research at the University of Toronto, is the principal investigator for the Toca 5 clinical trial in Canada. Dr. Zadeh and her team are working to open additional clinical trial sites across Canada as soon as we can to enable access to this trial for as many Canadians as possible. For more information on trial sites, please contact Dr. Zadeh firstname.lastname@example.org.
Learn more about Toca 5 Clinical Trial (http://tocagen.com/tocagen-expands-toca-5-phase-23-clinical-trial-for-recurrent-brain-cancer-to-canada/)
March 17, 2016